LinkPad: Access, safety and affordability

Providing access to safe, affordable medicines remains one of the most important goals of the health care industry. In honor of that charge, this week's LinkPad highlights the latest happenings in the areas of medicine access, safety, and affordability.

  • In an article for Forbes, Doug Schoen discusses the importance of reauthorizing the Prescription Drug User Fee Act (PDUFA) in providing access to medicines, stating, "If the PDUFA agreement passes as is, the FDA will have the much-needed resources and management tools to promote innovation through greater transparency, predictability, and efficacy in FDA's drug review program.  This, in turn, can help address unmet medical needs, stimulate the economy and create American jobs."
  • The Hill published an opinion piece by Representative John Dingell (D-MI) in which Dingell discusses how the user fee acts coming before Congress can be a vital tool to secure the drug-supply chain and ensure patient safety. The FDA currently lacks the necessary authority to monitor the supply chain; however, as Dingell demonstrates, "The authorization of the Generic Drug User Fee Act and the reauthorization of the Prescription Drug User Fee Act are wonderful opportunities to make significant drug-safety progress."
  • Earlier this week, the Center for Medicare and Medicaid Services highlighted recent findings on prescription drug savings for Medicare beneficiaries. Since the enactment of the Affordable Care Act, 3.6 million people enrolled in Medicare have saved $2.1 billion on prescription drugs. That works out to an average of $604 in savings per beneficiary. The White House supplemented these numbers on their blog with personal stories of how Medicare Part D has benefitted older Americans.

PDUFA V and Medicare Part D are imperative to providing top-of-the-line health care for American patients. For more information about PDUFA legislation and Medicare Part D in 2012, please visit the Campaign for Modern Medicines website and follow @modernmeds on Twitter.